Process of transition Sample Clauses

Process of transition. The transitional arrangements apply with effect from 1 April 2021. Eligible doctors will be entitled to express their interest to transfer to the TCS during a six-month choice window from 1 April 2021 to 30 September 2021. Where the doctor wishes to do so, they will enter into the process set out below. The process to transfer to the 2021 specialty doctor TCS shall be as follows:
AutoNDA by SimpleDocs
Process of transition. In the event that either party hereto elects to terminate this Agreement, the parties shall negotiate an orderly process of transition culminating in a written Transition Plan in accordance with the provisions of Attachment I hereto. The parties will meet within thirty (30) days of a party's election to terminate this Agreement and thereafter as set out in Attachment I. The parties' obligations under this Section 28.3 shall survive the termination or expiration of this Agreement.
Process of transition. In the event Amgen provides a notice to Purchaser of the intent to transition the manufacturing (either in the entirety, only the formulation, fill and finish manufacturing activities, or only the manufacture of Bulk Drug Substance (if Amgen has previously transitioned the formulation, fill and finish manufacturing activities)) of Drug Product (such manufacturing activities to be transitioned, the “Transitioned Manufacturing”), to an alternate source pursuant to Sections 2.9 (Changes to Manufacturing), 2.14.3 (Bulk Drug Substance), 7.4 (Termination by Amgen for Discontinuation) or 7.4 (Change of Control), then Amgen and Purchaser shall cooperate to transition the Transitioned Manufacturing to a mutually acceptable Third-Party manufacturer. Purchaser shall contract directly with the Third-Party manufacturer and shall be responsible for the Transitioned Manufacturing of Drug Product for Purchaser, its Affiliates and sublicensees for Licensee Indications in the Territory. Amgen shall cooperate to provide to such Third-Party manufacturer, under obligations of confidentiality, [*] such Transitioned Manufacturing of Drug Product for Purchaser in the Licensee Indications in the Territory. Amgen shall also, in connection therewith, grant to such Third-Party manufacturer a non-exclusive license to use such manufacturing technology solely for the purposes of performing the Transitioned Manufacturing of Drug Product for Purchaser for the Licensee Indications in the Territory. Purchaser shall be solely responsible for all costs associated with the transition to such Third-Party manufacturer (including payment at the FTE Rate for hours of [*] provided by Amgen) and all costs associated with the purchase of Drug Product from such Third-Party manufacturer. Amgen shall have no responsibility to Purchaser for Purchaser’s supply of Drug Product to be provided by a Third-Party manufacturer pursuant to this Section 2.14 (Alternate Supply).
Process of transition. The transitional arrangements apply with effect from 1 April 2021. Eligible doctors will be entitled to express their interest to transfer to the Terms and Conditions of Service during a 6-month choice window from 1 April 2021 to 31st October 2021. Where the doctor wishes to do so, they will enter into the process set out below.

Related to Process of transition

  • Execution of Transactions (a) In executing transactions for the Assets, selecting brokers or dealers and negotiating any brokerage commission rates, the Sub-Adviser will use its best efforts to seek the best overall terms available. In assessing the best overall terms available for any portfolio transaction, the Sub-Adviser will consider all factors it deems relevant including, but not limited to, the breadth of the market in the security, the price of the security, the financial condition and execution capability of the broker or dealer and the reasonableness of any commission for the specific transaction and for transactions executed through the broker or dealer in the aggregate. In selecting brokers or dealers to execute a particular transaction and in evaluating the best overall terms available, to the extent that the execution and price offered by more than one broker or dealer are comparable the Sub-Adviser may consider any brokerage and research services (as those terms are defined in Section 28(e) of the Securities Exchange Act of 1934) provided to the Sub-Adviser or to CSAM for use on behalf of the Fund or other clients of the Sub-Adviser or CSAM.

  • Description of Transaction 1.1 Merger of Merger Sub into the Company. Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time (as defined in Section 1.3), Merger Sub shall be merged with and into the Company, and the separate existence of Merger Sub shall cease. The Company will continue as the surviving corporation in the Merger (the “Surviving Corporation”).

  • Limitation of Transactions So long as any Capital Securities remain outstanding, if (a) there shall have occurred and be continuing an Event of Default or (b) the Guarantor shall have selected an Extension Period as provided in the Declaration and such period, or any extension thereof, shall have commenced and be continuing, then the Guarantor may not (x) declare or pay any dividends or distributions on, or redeem, purchase, acquire, or make a liquidation payment with respect to, any of the Guarantor's capital stock or (y) make any payment of principal of or interest or premium, if any, on or repay, repurchase or redeem any debt securities of the Guarantor that rank pari passu in all respects with or junior in interest to the Debentures (other than (i) payments under this Guarantee, (ii) repurchases, redemptions or other acquisitions of shares of capital stock of the Guarantor (A) in connection with any employment contract, benefit plan or other similar arrangement with or for the benefit of one or more employees, officers, directors, or consultants, (B) in connection with a dividend reinvestment or stockholder stock purchase plan or (C) in connection with the issuance of capital stock of the Guarantor (or securities convertible into or exercisable for such capital stock), as consideration in an acquisition transaction entered into prior to the occurrence of the Event of Default or the applicable Extension Period, (iii) as a result of any exchange or conversion of any class or series of the Guarantor's capital stock (or any capital stock of a subsidiary of the Guarantor) for any class or series of the Guarantor's capital stock or of any class or series of the Guarantor's indebtedness for any class or series of the Guarantor's capital stock, (iv) the purchase of fractional interests in shares of the Guarantor's capital stock pursuant to the conversion or exchange provisions of such capital stock or the security being converted or exchanged, (v) any declaration of a dividend in connection with any stockholder's rights plan, or the issuance of rights, stock or other property under any stockholder's rights plan, or the redemption or repurchase of rights pursuant thereto, or (vi) any dividend in the form of stock, warrants, options or other rights where the dividend stock or the stock issuable upon exercise of such warrants, options or other rights is the same stock as that on which the dividend is being paid or ranks pari passu with or junior to such stock).

  • As Of Transactions For purposes of this Article M, the term “

  • Documentation of Transfer Seller shall undertake to file the documents which would be necessary to perfect and maintain the transfer of the security interest in and to the Receivables and Other Conveyed Property.

  • Support of Transaction Without limiting any covenant contained in Article VI or Article VII, including the obligations of the Company and Acquiror with respect to the notifications, filings, reaffirmations and applications described in Section 6.03 and Section 7.01, respectively, which obligations shall control to the extent of any conflict with the succeeding provisions of this Section 8.01, Acquiror and the Company shall each, and Acquiror shall cause Merger Sub to: (a) use commercially reasonable efforts to assemble, prepare and file any information (and, as needed, to supplement such information) as may be reasonably necessary to obtain as promptly as practicable all governmental and regulatory consents required to be obtained in connection with the Transactions, (b) use commercially reasonable efforts to obtain all material consents and approvals of third parties that any of Acquiror, the Company, or their respective Affiliates are required to obtain in order to consummate the Transactions, including any required approvals of parties to Material Contracts with the Company, and (c) take such other action as may reasonably be necessary or as another party may reasonably request to satisfy the conditions of Article IX or otherwise to comply with this Agreement and to consummate the Transactions as soon as practicable. Notwithstanding the foregoing, in no event shall Acquiror, Merger Sub or the Company be obligated to bear any expense or pay any fee or grant any concession in connection with obtaining any consents, authorizations or approvals pursuant to the terms of any Contract to which the Company is a party or otherwise in connection with the consummation of the Transactions.

  • Non-Solicitation of Transfer Agent Employees The Fund shall not attempt to hire or assist with the hiring of an employee of the Transfer Agent or of its affiliated companies or encourage any employee to terminate their relationship with the Transfer Agent or its affiliated companies.

  • Nature of Transaction It is the intention of the parties that:

  • Replacement of Transfer Agent In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

  • Authorization of Transactions The Company is a corporation duly authorized and in good standing in the State of Florida and has the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to perform its obligations hereunder and thereunder. The execution, delivery and performance by the Company of the applicable Transaction Documents and the consummation of the Transactions have been duly and validly authorized by all requisite action on the part of the Company. The Transaction Documents to which the Company is a party have been duly and validly executed and delivered by The Company. Each Transaction Document to which the Company is a party constitutes the valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency or other Laws affecting the enforcement of creditors’ rights or by the principles governing the availability of equitable remedies.

Time is Money Join Law Insider Premium to draft better contracts faster.